Big Pharma leads the list of billion-dollar deals this week with a $40 billion, unsolicited bid made by Israel’s Teva Pharmaceutical Industries Ltd. for fellow generic-drug maker Mylan N.V.

Both companies have recently been busy in the deal space. In late March, Teva turned to Goodwin Procter for counsel on its $3.2 billion buy of La Jolla, California-based orphan-drug maker Auspex Pharmaceuticals, which was advised by Cooley.